Toggle

A drug, REGN7257, to treat severe aplastic anemia (SAA) that has come back (relapsed) or has not gotten better with treatment (refractory)

Print

18 and older

Phase 1, Phase 2

2 Locations

NCT04409080

Clinical Trial Goal


To find out:
  • The highest dose of REGN7257 that’s safe to give
  • If REGN7257 is safe and works well to treat SAA that has relapsed or is refractory

You may be able to join this trial if you:


  • Are 18 years old or older
  • Have SAA that has relapsed or is refractory after or during treatment with standard immunosuppressive therapy (IST)
  • Do not have Fanconi anemia (FA)
  • Have not been treated with alemtuzumab or anti-thymocyte globulin (ATG) in the last 6 months
  • Agree to have other standard tests done to see if you can be in the clinical trial 

Trial Details


REGN7257 is a monoclonal antibody that targets IL2 in certain cells.
 
You’ll get: 
  • REGN7257 – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been

You may continue treatment for as long as the clinical trial doctors think it’s best for your health. The doctors will check your health for up to 1 year.

The Food and Drug Administration (FDA) has not yet approved REGN7257.

Contacts


Clinical Trials Administrator, 844-734-6643, clinicaltrials@regeneron.com

Locations


Cleveland Clinic FoundationRecruiting

Cleveland, Ohio

The University of Texas MD Anderson Cancer CenterNot yet recruiting

Houston, Texas

ClinicalTrials.gov record


NCT04409080

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator

1-888-814-8610
contact@ctsearchsupport.org